On September 15, 2023, Robert Foster, the CEO, CSO, and Director of Hepion Pharmaceuticals Inc (NASDAQ:HEPA), made a significant insider purchase of 1,600 shares of the company's stock.

In addition, Edison-based Hepion said CEO and Director Robert Foster resigned from his positions for personal reasons, effective immediately. Chief Financial Officer John Cavan has been appointed ...

EDISON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven ...

In December, Hepion CEO and Director Robert Foster resigned from his positions for personal reasons and Chief Financial Officer John Cavan was appointed interim CEO. A.G.P./Alliance Global ...

Hepion Pharmaceuticals appoints Dr. Kaouthar Lbiati as interim CEO as it pivots to diagnostic tests for celiac, ... then-CEO and director Robert Foster resigned for personal reasons, ...

EDISON, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven ...

Hepion’s head honcho Robert Foster, Ph.D., has also resigned, citing personal reasons. Chief Financial Officer John Cavan has stepped up and will lead the biotech as interim CEO.

EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven ...

--Hepion Pharmaceuticals, Inc., ... thereby providing for a stronger and more diverse investor base,” commented Robert Foster, Chief Executive Officer of Hepion. ...

Hepion Pharmaceuticals, Inc. Approximately $2.9 Million from Sale of Its New Jersey State Net Operating Losses (“NOLs”), Plus $0.3 Million from Alberta Innovation Employment Grant ...

EDISON, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven ...